RxDoctor Payments Data

Wayne Paulekas, MD

Internal Medicine · Wethersfield, CTNPI 1730166422

Payments from drug & device makers

$3,896in general payments, 2019–2025

Across 220 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$585
  • Pfizer$473
  • AstraZeneca$458
  • GSK$276
  • Astellas Pharma US Inc$273
  • Johnson & Johnson$239
  • plus $2K from 35 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$3,87199%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,896 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$134,019
Medicare patients
285
Services billed
1,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$167,671
JardianceEmpagliflozin99$114,065
OzempicSemaglutide42$79,937
FarxigaDapagliflozin Propanediol88$79,636
XareltoRivaroxaban122$77,846
JanuviaSitagliptin Phosphate61$54,195
MyrbetriqMirabegron69$39,965
MounjaroTirzepatide31$37,429
EpidiolexCannabidiol (Cbd)19$35,729
GemtesaVibegron45$22,259
TrulicityDulaglutide17$17,141
LinzessLinaclotide15$13,369
Breo ElliptaFluticasone/Vilanterol26$12,256
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$12,130
OxycontinOxycodone Hcl23$7,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$473$167,671342 claims
Boehringer IngelheimJardiance$176$114,06599 claims
Novo NordiskOzempic$151$79,93742 claims
AstraZenecaFarxiga$458$79,63688 claims
Johnson & JohnsonXarelto$239$77,846122 claims
MerckJanuvia, Janumet Xr$13$60,62773 claims
Lilly USA, LLCMounjaro, Trulicity$44$54,57048 claims
Astellas Pharma US IncMyrbetriq$273$39,96569 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$276$26,87060 claims
Sumitomo Pharma America, Inc.Gemtesa$52$22,25945 claims
AbbVieLinzess$585$13,36915 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$4,423426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Wethersfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →